![ISPOR 2024 May 5-8, 2024 | Atlanta, GA, USA. Early Registration Rate expires March 28.]({"type":"image" , "src" : "/sda/112343/IJME-March-May.jpg"})
Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Issa J. Dahabreh, John B. Wong & Thomas A. Trikalinos. (2017) Validation and calibration of structural models that combine information from multiple sources. Expert Review of Pharmacoeconomics & Outcomes Research 17:1, pages 27-37.
Read now
Read now
Marie-Hélène Lafeuille, Amanda Melina Grittner, Jonathan Gravel, Robert A Bailey, Silas Martin, Lawrence Garber, Mei Sheng Duh & Patrick Lefebvre. (2015) Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control. Journal of Medical Economics 18:2, pages 113-125.
Read now
Read now
Katarina Steen Carlsson & Ulf Persson. (2014) Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin. Journal of Medical Economics 17:9, pages 658-669.
Read now
Read now
Articles from other publishers (23)
Marc Evans, Sasha Berry, Avideh Nazeri, Samuel JP Malkin, Donna Ashley, Barnaby Hunt & Stephen C Bain. (2022) The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes. Diabetes, Obesity and Metabolism 25:3, pages 639-648.
Crossref
Crossref
Tagoe Eunice Twumwaa, Nonvignon Justice, van Der Meer Robert & Megiddo Itamar. (2022) Application of decision analytical models to diabetes in low- and middle-income countries: a systematic review. BMC Health Services Research 22:1.
Crossref
Crossref
Sara Stafford, Peter G. Bech, Adam Fridhammar, Nino Miresashvili, Andreas Nilsson, Michael Willis & Aiden Liu. (2022) Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting. Applied Health Economics and Health Policy 20:4, pages 543-555.
Crossref
Crossref
Elton Mukonda, Susan Cleary & Maia Lesosky. (2021) A review of simulation models for the long-term management of type 2 diabetes in low-and-middle income countries. BMC Health Services Research 21:1.
Crossref
Crossref
Jiayu Li, Yun Bao, Xuedi Chen & Limin Tian. (2021) Decision models in type 2 diabetes mellitus: A systematic review. Acta Diabetologica 58:11, pages 1451-1469.
Crossref
Crossref
Jose Leal, Maria Alva, Vanessa Gregory, Alison Hayes, Borislava Mihaylova, Alastair M. Gray, Rury R. Holman & Philip Clarke. (2021) Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90). Diabetic Medicine 38:10.
Crossref
Crossref
Michael Willis, Adam Fridhammar, Jens Gundgaard, Andreas Nilsson & Pierre Johansen. (2020) Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM. PharmacoEconomics 38:9, pages 953-969.
Crossref
Crossref
Pierre Johansen, Jonas Håkan-Bloch, Aiden R. Liu, Peter G. Bech, Sofie Persson & Lawrence A. Leiter. (2019) Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada. PharmacoEconomics - Open 3:4, pages 537-550.
Crossref
Crossref
Daniel M. Sugrue, Thomas Ward, Sukhvir Rai, Phil McEwan & Heleen G. M. van Haalen. (2019) Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design. PharmacoEconomics 37:12, pages 1451-1468.
Crossref
Crossref
Nasuh C. Büyükkaramikli, Maureen P. M. H. Rutten-van Mölken, Johan L. Severens & Maiwenn Al. (2019) TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility. PharmacoEconomics 37:11, pages 1391-1408.
Crossref
Crossref
Vishal Gupta, Michael Willis, Pierre Johansen, Andreas Nilsson, Manan Shah, Amey Mane & Cheryl Neslusan. (2019) Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India. Value in Health Regional Issues 18, pages 65-73.
Crossref
Crossref
Mohammad Z.I. Chowdhury, Fahmida Yeasmin, Doreen M. Rabi, Paul E. Ronksley & Tanvir C. Turin. (2019) Prognostic tools for cardiovascular disease in patients with type 2 diabetes: A systematic review and meta-analysis of C-statistics. Journal of Diabetes and its Complications 33:1, pages 98-111.
Crossref
Crossref
Katharina Fritzen, Lutz Heinemann & Oliver Schnell. (2018) Modeling of Diabetes and Its Clinical Impact. Journal of Diabetes Science and Technology 12:5, pages 976-984.
Crossref
Crossref
Cheryl Neslusan, Anna Teschemaker, Michael Willis, Pierre Johansen & Lien Vo. (2018) Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States. Diabetes Therapy 9:2, pages 565-581.
Crossref
Crossref
Michael Willis, Pierre Johansen, Andreas Nilsson & Christian Asseburg. (2016) Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM). PharmacoEconomics 35:3, pages 375-396.
Crossref
Crossref
Xinyang Hua, Thomas Wai-Chun Lung, Andrew Palmer, Lei Si, William H. Herman & Philip Clarke. (2016) How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review. PharmacoEconomics 35:3, pages 319-329.
Crossref
Crossref
Puneet Gaitonde, Parag Garhyan, Catharina Link, Jenny Y. Chien, Mirjam N. Trame & Stephan Schmidt. (2016) A Comprehensive Review of Novel Drug?Disease Models in Diabetes Drug Development. Clinical Pharmacokinetics 55:7, pages 769-788.
Crossref
Crossref
Lindsay Govan, Olivia Wu, Robert Lindsay & Andrew Briggs. (2015) How Do Diabetes Models Measure Up? A Review of Diabetes Economic Models and ADA Guidelines. Journal of Health Economics and Outcomes Research 3:2, pages 132-152.
Crossref
Crossref
A. A. W. A. van der Heijden, T. L. Feenstra, R. T. Hoogenveen, L. W. Niessen, M. C. de Bruijne, J. M. Dekker, C. A. Baan & G. Nijpels. (2015) Policy evaluation in diabetes prevention and treatment using a population-based macro simulation model: the MICADO model. Diabetic Medicine 32:12, pages 1580-1587.
Crossref
Crossref
Cheryl Neslusan, Anna Teschemaker, Pierre Johansen, Michael Willis, Atanacio Valencia-Mendoza & Andrea Puig. (2015) Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico. Value in Health Regional Issues 8, pages 8-19.
Crossref
Crossref
Simone Marini, Emanuele Trifoglio, Nicola Barbarini, Francesco Sambo, Barbara Di Camillo, Alberto Malovini, Marco Manfrini, Claudio Cobelli & Riccardo Bellazzi. (2015) A Dynamic Bayesian Network model for long-term simulation of clinical complications in type 1 diabetes. Journal of Biomedical Informatics 57, pages 369-376.
Crossref
Crossref
Adam Lundqvist, Katarina Steen Carlsson, Pierre Johansen, Emelie Andersson & Michael Willis. (2014) Validation of the IHE Cohort Model of Type 2 Diabetes and the Impact of Choice of Macrovascular Risk Equations. PLoS ONE 9:10, pages e110235.
Crossref
Crossref
J. Jaime Caro, David M. Eddy, Hong Kan, Cheryl Kaltz, Bimal Patel, Randa Eldessouki & Andrew H. Briggs. (2014) Questionnaire to Assess Relevance and Credibility of Modeling Studies for Informing Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report. Value in Health 17:2, pages 174-182.
Crossref
Crossref